Adage Capital Partners Gp Llc Decreased Calithera Biosciences (CALA) Stake By $15.58 Million; Shorts at Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Raised By 11.23%

February 16, 2018 - By Nellie Frank

Adage Capital Partners Gp Llc decreased Calithera Biosciences Inc (NASDAQ:CALA) stake by 56.49% reported in 2017Q4 SEC filing. Adage Capital Partners Gp Llc sold 1.95 million shares as Calithera Biosciences Inc (NASDAQ:CALA)’s stock rose 75.00%. The Adage Capital Partners Gp Llc holds 1.50 million shares with $12.53 million value, down from 3.45 million last quarter. Calithera Biosciences Inc now has $302.63M valuation. The stock increased 22.74% or $1.5805 during the last trading session, reaching $8.5305. About 2.63M shares traded or 342.12% up from the average. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 16, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Corindus Vascular Robotics Incorporated (NYSEAMERICAN:CVRS) had an increase of 11.23% in short interest. CVRS’s SI was 11.39M shares in February as released by FINRA. Its up 11.23% from 10.24 million shares previously. With 975,300 avg volume, 12 days are for Corindus Vascular Robotics Incorporated (NYSEAMERICAN:CVRS)’s short sellers to cover CVRS’s short positions. The SI to Corindus Vascular Robotics Incorporated’s float is 37.56%. The stock increased 5.26% or $0.05 during the last trading session, reaching $1. About 201,910 shares traded. Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) has risen 8.65% since February 16, 2017 and is uptrending. It has underperformed by 8.05% the S&P500.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $302.63 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It fall, as 16 investors sold CALA shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. Manufacturers Life The stated it has 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Credit Suisse Ag invested 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Raymond James Financial Services Advisors Inc owns 17,000 shares. New York-based Tiaa Cref Inv Management Ltd Liability has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Barclays Public Limited Co stated it has 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Moreover, Trexquant Invest Ltd Partnership has 0.04% invested in Calithera Biosciences, Inc. (NASDAQ:CALA). Atika Capital Ltd Company accumulated 234,603 shares. Gsa Capital Prtn Ltd Liability Partnership owns 30,257 shares or 0.03% of their US portfolio. Franklin Street Advsrs Nc invested 0.09% in Calithera Biosciences, Inc. (NASDAQ:CALA). Ny State Common Retirement Fund stated it has 32,700 shares or 0% of all its holdings. Vanguard Gp Incorporated invested in 1.10M shares. State Board Of Administration Of Florida Retirement stated it has 15,177 shares or 0% of all its holdings. Citadel Advisors Limited Liability Corporation owns 480,673 shares or 0.01% of their US portfolio. Clarivest Asset Management Ltd Liability Corporation holds 0.02% or 49,474 shares in its portfolio. California State Teachers Retirement System has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA).

Adage Capital Partners Gp Llc increased Alkermes Plc (NASDAQ:ALKS) stake by 275,000 shares to 400,000 valued at $21.89M in 2017Q4. It also upped Twenty First Centy Fox Inc (NASDAQ:FOXA) stake by 1.37 million shares and now owns 1.50 million shares. Nextera Energy Inc (NYSE:NEE) was raised too.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup upgraded Calithera Biosciences, Inc. (NASDAQ:CALA) rating on Friday, February 16. Citigroup has “Buy” rating and $14.0 target. As per Monday, June 12, the company rating was maintained by H.C. Wainwright. Citigroup upgraded the shares of CALA in report on Tuesday, January 24 to “Neutral” rating. H.C. Wainwright initiated Calithera Biosciences, Inc. (NASDAQ:CALA) on Thursday, January 5 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Tuesday, March 28. Citigroup initiated Calithera Biosciences, Inc. (NASDAQ:CALA) on Tuesday, October 25 with “Sell” rating. The company was initiated on Friday, July 24 by Citigroup. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9.

Phil Gross and Robert Atchinson founded Adage in the year 2001 and based it in Boston. Before they became partners is heralding their own company, the two were poised on different facets of the business before they met at Harvard Management Company. It was Phil Gross who first started to work for them as their healthcare and retail analyst. He later on became a lucrative partner of the firm, to which he stayed for about 18 years. Robert Atchinson, on the other hand, began his involvement with the company in 1991 and that’s how the two became partner analysts. Based on the information published in the Harvard Magazine, their team managed to best the S&P 500 index with an average percentage of 4.5 points in an annual basis. Now, Adage is hired by HMC to manage about $1.8 billion of their funds and they also basically hold a minority interest in Adage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.